{
  "meta": {
    "timestamp": "2025-01-06T12:50:18.303821",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Organon & Co",
      "symbol": "OGN",
      "analysis": {
        "historical": {
          "risk_score": 60,
          "key_risks": [
            "Patent and legal challenges, including recent settlements and ongoing risks from intellectual property disputes",
            "Regulatory risks, such as delays in FDA approvals and stringent oversight",
            "Market competition from larger pharmaceutical firms and generic drug manufacturers",
            "Supply chain vulnerabilities due to reliance on third-party manufacturers",
            "Financial and growth challenges, including limited growth potential and reliance on key products"
          ],
          "controversies": [
            "High-stakes patent lawsuit over Nexplanon, a key revenue driver",
            "Public scrutiny over access to contraceptives and reproductive health services"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Focus on women\u2019s health, including access to contraceptives and reproductive health services",
            "Ethical considerations related to public perception of women\u2019s health initiatives"
          ],
          "governance_issues": [
            "Regulatory compliance and oversight in a highly regulated industry",
            "Management of legal disputes and intellectual property risks"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Organon Settles Nexplanon Patent-Royalties Suit on Eve of Trial",
              "snippet": "Merck & Co. spinoff's CEO sees drug as blockbuster by 2025 Organon & Co. and a patent-holding company backed by litigation funders settled a long-pending federal lawsuit over patent royalties for the contraceptive implant Nexplanon, scuttling a jury trial that had been set to begin Monday.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co patent litigation",
              "retrieved_at": "2025-01-06T19:49:48.086957+00:00",
              "published_date": null,
              "source_hash": "0d475c571e76912adabf93e18bcb1b39"
            },
            {
              "url": "",
              "title": "Funders Unmasked in 2017 Patent Suit Over Organon's Nexplanon",
              "snippet": "A patent-holding firm seeking royalties from Nexplanon, a contraceptive implant whose US sales were nearly 10% of Merck & Co. spinoff Organon & Co.'s 2022 revenue, revealed in a court filing that two litigation funders are fueling Microspherix LLC's 2017 infringement suit.. Microspherix is owned by Edward J. Kaplan, the sole named inventor of the asserted patents.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co patent litigation",
              "retrieved_at": "2025-01-06T19:49:48.087058+00:00",
              "published_date": null,
              "source_hash": "9e1a54202a18d0555d3fc24b9a1ea412"
            },
            {
              "url": "",
              "title": "Organon, Microspherix make headway on Nexplanon patents dispute",
              "snippet": "Organon, Microspherix make headway on Nexplanon patents dispute Jun. 25, 2021 3:58 PM ET Merck & Co., Inc. (MRK) Stock , OGN Stock MRK , OGN By: Jonathan Block , SA News Editor putilich/iStock via ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co patent litigation",
              "retrieved_at": "2025-01-06T19:49:48.087073+00:00",
              "published_date": null,
              "source_hash": "ad914945e2a92b1e36861678e583c745"
            },
            {
              "url": "",
              "title": "Funders Unmasked in 2017 Patent Suit Over Organon's Nexplanon",
              "snippet": "A court filing has revealed that a GLS Capital affiliate and Law Finance Group are funding a patent infringement suit brought by Microspherix against Nexplanon, Litigation Finance Insider. Categories. League ... Litigation Finance Insider; Posts; Funders Unmasked in 2017 Patent Suit Over Organon's Nexplanon; Funders Unmasked in 2017 Patent ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co patent litigation",
              "retrieved_at": "2025-01-06T19:49:48.087084+00:00",
              "published_date": null,
              "source_hash": "94d026f364609e081f670f38f117bd3d"
            },
            {
              "url": "",
              "title": "Organon, Inc. v. Teva Pharmaceuticals, Inc., 244 F. Supp ... - Justia Law",
              "snippet": "This lawsuit is brought by Organon and Akzo pursuant to 35 U.S.C. \u00a7 271(e) (2), a provision of the Hatch-Waxman Act, which regulates the process to be used by the Food and Drug Administration (\"FDA\") in approving new and generic pharmaceutical drugs. ... Hewlett-Packard Co. v. Bausch & Lomb Inc., 909 F.2d 1464, 1469 (Fed.Cir.1990). \"It must be ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co patent litigation",
              "retrieved_at": "2025-01-06T19:49:48.087094+00:00",
              "published_date": null,
              "source_hash": "24a768199f577214a84ff9574e19c24f"
            },
            {
              "url": "",
              "title": "Merck Sharp & Dohme Corp. et al v. Microspherix LLC | Law.co...",
              "snippet": "Gibson, Dunn & Crutcher and McCarter & English filed a patent lawsuit Tuesday in New Jersey District Court on behalf of Organon USA Inc. and its former parent company Merck.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co patent litigation",
              "retrieved_at": "2025-01-06T19:49:48.087108+00:00",
              "published_date": null,
              "source_hash": "dc62da83672a519b175e605de78626b4"
            },
            {
              "url": "",
              "title": "Organon & Co. - Entity | RPX Insight",
              "snippet": "Organon & Co. has 23 patent litigation cases (1 case currently active) - 1 patent asserted - 18 cases as a plaintiff - 5 cases as a defendant",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co patent litigation",
              "retrieved_at": "2025-01-06T19:49:48.087117+00:00",
              "published_date": null,
              "source_hash": "ec9c77affca1e5f6cd4f808c47194c50"
            },
            {
              "url": "",
              "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of ...",
              "snippet": "NEW YORK, Feb. 22, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (\"Organon\" or the \"Company\") (NYSE: OGN).Such investors are advised to contact ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co patent litigation",
              "retrieved_at": "2025-01-06T19:49:48.087127+00:00",
              "published_date": null,
              "source_hash": "2bb74c53fcc42e72a4198bf4e0ccc1a6"
            },
            {
              "url": "",
              "title": "U.S. v. Organon, Inc. - Casetext",
              "snippet": "A. Factual Background. Plaintiff/Relator, Jeffrey D. Feldstein, M.D.'s (\"Relator\") qui tam action alleges that Organon intentionally withheld information from the FDA when it sought and eventually obtained FDA approval of Raplon\u00ae, a neuromuscular blocking agent. Organon is a pharmaceutical company which engages in the creating, manufacturing, distributing, and marketing of pharmaceuticals ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co patent litigation",
              "retrieved_at": "2025-01-06T19:49:48.087138+00:00",
              "published_date": null,
              "source_hash": "6cd2704a4434b7a02540a7db8711cebe"
            },
            {
              "url": "",
              "title": "ogn-20220331 - SEC.gov",
              "snippet": "Organon & Co. (\"Organon\" or the \"Company\") is a global health care company formed through a spinoff from Merck & Co., Inc. (\"Merck\") to focus on improving the health of women throughout their lives. ... against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co patent litigation",
              "retrieved_at": "2025-01-06T19:49:48.087148+00:00",
              "published_date": null,
              "source_hash": "85ffd6385a1277da78fd5bedbb5c3505"
            },
            {
              "url": "",
              "title": "Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It",
              "snippet": "Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co patent litigation",
              "retrieved_at": "2025-01-06T19:49:51.767038+00:00",
              "published_date": "2024-12-09T16:58:00+00:00",
              "source_hash": "0e4b62391c8d9fe0e38612adb03f2ce3"
            },
            {
              "url": "",
              "title": "Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know",
              "snippet": "Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co patent litigation",
              "retrieved_at": "2025-01-06T19:49:51.767131+00:00",
              "published_date": "2024-11-04T15:18:00+00:00",
              "source_hash": "eb3e4ea84fb176da6450951a48370166"
            },
            {
              "url": "",
              "title": "Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It",
              "snippet": "Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co patent litigation",
              "retrieved_at": "2025-01-06T19:49:51.767159+00:00",
              "published_date": "2024-11-15T15:08:00+00:00",
              "source_hash": "e06e4bfcf1336d2c8434783d4f21ab3e"
            },
            {
              "url": "",
              "title": "Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know",
              "snippet": "Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co patent litigation",
              "retrieved_at": "2025-01-06T19:49:51.767183+00:00",
              "published_date": "2024-12-20T15:22:00+00:00",
              "source_hash": "b07ca2c1e8299ab716122855e99412c4"
            },
            {
              "url": "",
              "title": "Organon Settles Nexplanon Patent-Royalties Suit on Eve of Trial",
              "snippet": "Organon & Co. and a patent-holding company backed by litigation funders settled a long-pending federal lawsuit over patent royalties for the contraceptive implant Nexplanon, scuttling a jury trial that had been set to begin Monday. ... Microspherix LLC and the co-defendants told Judge Ren\u00e9e Marie Bumb during a five-minute video status ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Organon & Co Organon & Co controversies women's health access",
              "retrieved_at": "2025-01-06T19:49:53.208841+00:00",
              "published_date": null,
              "source_hash": "318df1df18ae1f0279b83af86b5dda6b"
            },
            {
              "url": "",
              "title": "Organon Issues 2023 ESG Report, Highlighting Strides in Women's Health ...",
              "snippet": "JERSEY CITY, N.J. - September 17, 2024 - Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today released its 2023 Environmental, Social and Governance (ESG) Report . Central to its mission to advance the health of women, the company focuses its ESG efforts on three core areas: Advancing Her Equity , innovating to support and expand access to women's ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Organon & Co Organon & Co controversies women's health access",
              "retrieved_at": "2025-01-06T19:49:53.208975+00:00",
              "published_date": null,
              "source_hash": "79d3560111fe5e8269e83c5836bfe5de"
            },
            {
              "url": "",
              "title": "Introducing Organon - Women's Health",
              "snippet": "Organon is a women's health company focused on collaborating with healthcare providers to bring innovative solutions that address the many unmet healthcare needs women face. ... and expand choice by finding and advancing potential solutions that help address critical gaps in women's health. ... Organon formed through a spin-off from Merck ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Organon & Co Organon & Co controversies women's health access",
              "retrieved_at": "2025-01-06T19:49:53.209008+00:00",
              "published_date": null,
              "source_hash": "5f47f811b8bf491b42459fbebc574c5f"
            },
            {
              "url": "",
              "title": "Merck pulls back the curtain on Organon with declining women's health ...",
              "snippet": "Merck & Co. is offering a first full look at Organon, the new company it's spinning off with its women's health and biosimilar portfolio. And for a company aspiring to be the leading women's ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Organon & Co Organon & Co controversies women's health access",
              "retrieved_at": "2025-01-06T19:49:53.209037+00:00",
              "published_date": null,
              "source_hash": "b2cadf40cf7c15fdece700ed11bef609"
            },
            {
              "url": "",
              "title": "Why pharma should redefine 'women's health' | PharmaVoice",
              "snippet": "Women's health investment has yo-yoed in recent years, but broadening and rethinking how pharma defines the sector could invite more interest \u2014 and move the needle on key health challenges. Organon, a 2021 Merck & Co. spinout focused entirely on women's health, is putting that broader focus into practice. \"Women's health is far too ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Organon & Co Organon & Co controversies women's health access",
              "retrieved_at": "2025-01-06T19:49:53.209059+00:00",
              "published_date": null,
              "source_hash": "a8a11671e17ca12f07ab9553c3492463"
            },
            {
              "url": "",
              "title": "Women's health 'missing out' because of male-dominated investment",
              "snippet": "Jessica Federer, managing director of Supernode Ventures, who is raising a $50mn fund to invest in women's health technology, said Organon's dealmaking in the sector should be an example to ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Organon & Co Organon & Co controversies women's health access",
              "retrieved_at": "2025-01-06T19:49:53.209088+00:00",
              "published_date": null,
              "source_hash": "aec840ac7b1ccf12121d8deaded05487"
            },
            {
              "url": "",
              "title": "Organon builds pipeline for women's health but can't do it alone",
              "snippet": "Like most women, Organon wears many hats with its three core areas: women's health, biosimilars and legacy products. In the last 20 months, the company has looked at over 400 potential pipeline ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Organon & Co Organon & Co controversies women's health access",
              "retrieved_at": "2025-01-06T19:49:53.209111+00:00",
              "published_date": null,
              "source_hash": "99ce310cce9cd174867ada8888d9b1c6"
            },
            {
              "url": "",
              "title": "Ahead of International Women's Day, Organon Calls for Recognition of ...",
              "snippet": "In its second year as a company, 10,000 employees around the world will receive paid time off to dedicate International Women's Day in service of women's health JERSEY CITY, N.J.\u2014 February 7, 2023 - For far too long, women's health issues have been underfunded, under researched and underserved. Leading up to International Women's Day on March 8, Organon (NYSE: OGN), a global women ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Organon & Co Organon & Co controversies women's health access",
              "retrieved_at": "2025-01-06T19:49:53.209133+00:00",
              "published_date": null,
              "source_hash": "3ef1b4f1e9eead50c74202cdc6f16294"
            },
            {
              "url": "",
              "title": "What is Organon? Why TXMD shareholders should care. : r/TXMD - Reddit",
              "snippet": "And both companies are dedicated to women's health. Also, the Merck 10k (annual report filing) for 2020 states that the spin-off of Organon is \"expected to be completed late in the second quarter of 2021. If you search Organon on Merck's website, you can see that they are prolifically hiring around the world to staff up Organon.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Organon & Co Organon & Co controversies women's health access",
              "retrieved_at": "2025-01-06T19:49:53.209159+00:00",
              "published_date": null,
              "source_hash": "7e4b438c45d89b686e2b5f7b49ea5719"
            },
            {
              "url": "",
              "title": "Organon doubles down on women's health focus - Drug Discovery and ...",
              "snippet": "In the realm of women's health, o ne area of focus is endometriosis, a chronic and often painful disorder that affects up to one in 10 women of reproductive age. Organon is pursuing a novel treatment for the condition, which it acquired through its acquisition of Forendo Pharma, which it first announced in late 2021.The OG-6219 compound, an investigational oral 17\u03b2-hydroxysteroid ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Organon & Co Organon & Co controversies women's health access",
              "retrieved_at": "2025-01-06T19:49:53.209182+00:00",
              "published_date": null,
              "source_hash": "c351e49f6c25bd36c55559edecdd2d13"
            },
            {
              "url": "",
              "title": "Organon Beats On Q1, Women's Health Leads the Charge",
              "snippet": "Organon & Co (NYSE:OGN) reported a 5% Y/Y increase in the first quarter of 2024 revenue, reaching around $1.622 billion, beating the consensus of $1.563 billion. Women's Health revenue increased ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Organon & Co Organon & Co controversies women's health access",
              "retrieved_at": "2025-01-06T19:49:55.798402+00:00",
              "published_date": "2024-05-02T20:17:00+00:00",
              "source_hash": "8030dd2857ffae4a9da758328deacfe5"
            },
            {
              "url": "",
              "title": "Organon makes women's health a priority",
              "snippet": "Learning about women's health needs helps to guide Organon's business strategy, and often the best way to learn is to listen. Therefore, Organon has made listening to women its main focus.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Organon & Co Organon & Co controversies women's health access",
              "retrieved_at": "2025-01-06T19:49:55.798679+00:00",
              "published_date": "2021-08-20T00:00:00+00:00",
              "source_hash": "a85bfb17cd812f545ab39bfcb095179f"
            },
            {
              "url": "",
              "title": "Cautious Outlook on Organon: Sell Rating Due to Limited Growth Potential and Market Challenges",
              "snippet": "Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Organon & Co Organon & Co controversies women's health access",
              "retrieved_at": "2025-01-06T19:49:55.798791+00:00",
              "published_date": "2024-12-12T04:56:00+00:00",
              "source_hash": "e3a18594ea8f9f7ee5d1b6bda3492393"
            },
            {
              "url": "",
              "title": "Organon & Co. (OGN)",
              "snippet": "Organon & Co. ( NYSE:OGN ) shareholders ... advancement of care and research in women's health, are collaborating to show their support for universal access to contraception in Canada.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Organon & Co Organon & Co controversies women's health access",
              "retrieved_at": "2025-01-06T19:49:55.798836+00:00",
              "published_date": "2025-01-03T00:00:00+00:00",
              "source_hash": "56a1faf84a35c9e37937de69c0951a8d"
            },
            {
              "url": "",
              "title": "Organon & Co. (NYSE:OGN) Announces Resignation of Board Member Martha E. McGarry",
              "snippet": "Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Organon & Co Organon & Co controversies women's health access",
              "retrieved_at": "2025-01-06T19:49:55.798882+00:00",
              "published_date": "2024-12-08T23:59:00+00:00",
              "source_hash": "74c2413588280a767ceb1714ae679538"
            },
            {
              "url": "",
              "title": "Organon stock on watch as FDA delays VTAMA label (OGN:NYSE)",
              "snippet": "Organon updates outlook as FDA delays VTAMA label expansion Nov. 05, 2024 7:53 AM ET Organon & Co. (OGN) Stock MRK By: Dulan Lokuwithana , SA News Editor 4 Comments Play ( 1min )",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co regulatory approval delays",
              "retrieved_at": "2025-01-06T19:49:57.288924+00:00",
              "published_date": null,
              "source_hash": "b41320f58a52d9eeb858b27e01abdfa9"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "ORGANON & CO. 2024 Annual Meeting of Shareholders Tuesday, June 4, 2024 ... including obtaining regulatory approval; the company's ability to accurately predict its future financial results and performance; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; difficulties developing and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co regulatory approval delays",
              "retrieved_at": "2025-01-06T19:49:57.289045+00:00",
              "published_date": null,
              "source_hash": "98828ce44603adc0a86c497b7a3d2383"
            },
            {
              "url": "",
              "title": "Organon & Lilly Expand Migraine Commercialization Agreement to 11 ...",
              "snippet": "The agreement builds on Organon's global product portfolio for conditions that impact women disproportionately. Women are three times more likely to experience migraine than men. i Organon (NYSE: OGN), a global healthcare company with a focus on women's health, announced it has expanded its agreement with Eli Lilly and Company (Lilly) to become the sole distributor and promoter for the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co regulatory approval delays",
              "retrieved_at": "2025-01-06T19:49:57.289061+00:00",
              "published_date": null,
              "source_hash": "91c76372a39d47e839bbb2c9c0e3d213"
            },
            {
              "url": "",
              "title": "Organon: A Surprising Deal (NYSE:OGN) | Seeking Alpha",
              "snippet": "Summary. Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re-rating. After a softer second quarter, Organon's 2024 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co regulatory approval delays",
              "retrieved_at": "2025-01-06T19:49:57.289074+00:00",
              "published_date": null,
              "source_hash": "522003b3dd33e546e958220aa944d183"
            },
            {
              "url": "",
              "title": "Organon and ObsEva Enter Global License Agreement to Develop and ...",
              "snippet": "JERSEY CITY, N.J. & GENEVA, Switzerland--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global women's health company and ObsEva (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company dedicated to improving women's reproductive health, today announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co regulatory approval delays",
              "retrieved_at": "2025-01-06T19:49:57.289085+00:00",
              "published_date": null,
              "source_hash": "a4e41279fae299f6b273e001cb2cd69f"
            },
            {
              "url": "",
              "title": "News - Organon",
              "snippet": "News. The information contained in each news release posted on this page was factually accurate on the date it was issued. The company assumes no duty to update the information to reflect subsequent developments.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co regulatory approval delays",
              "retrieved_at": "2025-01-06T19:49:57.289095+00:00",
              "published_date": null,
              "source_hash": "7eba4b948dc2a309f1c31d51b7883f5d"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "Organon & Co. will pay Merck an $8 to $9 billion special dividend prior to the spinoff, to be ... including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co regulatory approval delays",
              "retrieved_at": "2025-01-06T19:49:57.289104+00:00",
              "published_date": null,
              "source_hash": "8c1acadac906d1f0d12f5b6251b155a2"
            },
            {
              "url": "",
              "title": "Merck : Announces Completion of Organon & Co. Spinoff",
              "snippet": "Merck , known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. . \"Today marks a significant milestone for both Merck and Organon. ... including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co regulatory approval delays",
              "retrieved_at": "2025-01-06T19:49:57.289112+00:00",
              "published_date": null,
              "source_hash": "d2d7439b652e8b4cf3da2a24a4ebbfcd"
            },
            {
              "url": "",
              "title": "What can we help you find? - Merck",
              "snippet": "Organon Proposed Board of Directors To Have More Women Than Any S&P 500 Healthcare Company. ... including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co regulatory approval delays",
              "retrieved_at": "2025-01-06T19:49:57.289135+00:00",
              "published_date": null,
              "source_hash": "c39d200c4722df4b7246e99d095084c4"
            },
            {
              "url": "",
              "title": "ORGANON & CO. Management's Discussion and Analysis of Financial ...",
              "snippet": "The notes were assumed by Organon and the Dutch Co-Issuer. In addition, on June 2, 2021 , we entered into a credit agreement providing for a $3.0 billion U.S. dollar-denominated senior secured term loan due 2028 and a euro denominated senior secured term loan in the amount of \u20ac750 million due 2028.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co regulatory approval delays",
              "retrieved_at": "2025-01-06T19:49:57.289146+00:00",
              "published_date": null,
              "source_hash": "2fd545f4410e69d22bf96bed1220925c"
            },
            {
              "url": "",
              "title": "Cautious Outlook on Organon: Sell Rating Due to Limited Growth Potential and Market Challenges",
              "snippet": "While the potential early approval for VTAMA in atopic ... Begin your TipRanks Premium journey today. Organon (OGN) Company Description: Organon & Co is a science-based global pharmaceutical ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co regulatory approval delays",
              "retrieved_at": "2025-01-06T19:50:00.706387+00:00",
              "published_date": "2024-12-12T04:56:00+00:00",
              "source_hash": "16b0afe5ef13603d9388c5f605f98073"
            },
            {
              "url": "",
              "title": "Organon & Co. (OGN)",
              "snippet": "cream is a first-in-class therapy with new FDA approval for atopic dermatitis in adults and children aged 2 and older. Organon & Co. ( NYSE:OGN ) shareholders are probably feeling a little ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co regulatory approval delays",
              "retrieved_at": "2025-01-06T19:50:00.706528+00:00",
              "published_date": "2025-01-03T00:00:00+00:00",
              "source_hash": "54bdee372d5916a93b2e9f9b9fc72af3"
            },
            {
              "url": "",
              "title": "Organon & Co. announces board member resignation",
              "snippet": "Organon & Co. (NYSE:OGN), a pharmaceutical company ... considered a major amendment to the sNDA. Despite this delay, Organon anticipates VTAMA will generate approximately $125 million in revenue ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co regulatory approval delays",
              "retrieved_at": "2025-01-06T19:50:00.706562+00:00",
              "published_date": "2024-12-06T17:58:00+00:00",
              "source_hash": "606e8a2d0913459d752d6d4519a22081"
            },
            {
              "url": "",
              "title": "FDA approves Organon's VTAMA cream, 1% for the treatment for AD",
              "snippet": "Organon (OGN) announced that the U.S. Food and Drug Administration or FDA has approved VTAMA or tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Organon & Co Organon & Co regulatory approval delays",
              "retrieved_at": "2025-01-06T19:50:00.706589+00:00",
              "published_date": "2024-12-16T06:40:00+00:00",
              "source_hash": "e9a1e5f7085ba55f4a6923c04bdd5e77"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Organon & Co patent litigation",
              "rationale": "Investigate legal challenges related to patent expirations and generic competition",
              "priority": 1
            },
            {
              "category": "ethical_social",
              "query": "Organon & Co controversies women's health access",
              "rationale": "Explore public perception and ethical concerns regarding access to contraceptives and reproductive health services",
              "priority": 2
            },
            {
              "category": "financial_legal",
              "query": "Organon & Co regulatory approval delays",
              "rationale": "Assess risks associated with delays or rejections in product approvals by regulatory bodies",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T12:50:18.303834",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}